Cinpanemab

Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease[1][2].

Research Areas >> Neurological Disease

α-synuclein[1]

Cinpanemab 对聚合形式的 α-syn 具有高度选择性，对纤维状重组 α-syn 的表观亲和力至少比单体重组 α-syn 高 800 倍，并且对人 PD 脑组织有强烈的偏好[2]。

Cinpanemab (30 mg/kg; 腹腔注射) 改善 α-syn PFF 接种小鼠模型中的 PD 样表型[2]。 Animal Model: C57BL/6JRccHsd WT mice, transgenic M83 mice expressing human α-syn A53T, and transgenic bacterial artificial chromosome mice expressing human α-syn A53T were anesthetized and stereotaxically injected with α-syn preformed fibrils (PFFs) into the right forebrain[2] Dosage: 30 mg/kg Administration: Intraperitoneal (i.p.) injections 2-3 times prior to α-syn PFF injection and weekly post-injection until time of sacrifice Result: Attenuated the spreading of α-syn pathology, rescued motor impairments, and reduced the loss of dopamine transporter density in dopaminergic terminals in striatum.

[1]. Lang AE, et, al. Trial of Cinpanemab in Early Parkinson's Disease. N Engl J Med. 2022 Aug 4;387(5):408-420.  

[2]. Teng JS, et, al. Immunotherapies for Parkinson's Disease: Progression of Clinical Development. CNS Neurol Disord Drug Targets. 2021;20(9):802-813.